Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.76)
# 3,979
Out of 5,006 analysts
58
Total ratings
34%
Success rate
-25.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Assumes: Buy | $11 | $5.26 | +109.13% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $17.40 | +78.16% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $0.95 | +1,889.74% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $7.19 | +192.07% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $3.70 | +35.14% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $1.91 | +737.70% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $120 | $1.60 | +7,400.00% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $7.36 | +239.67% | 2 | May 14, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Neutral | n/a | $8.82 | - | 3 | Mar 14, 2024 | |
| BDRX Biodexa Pharmaceuticals | Initiates: Buy | $2,000 | $6.85 | +29,097.08% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.44 | +386.11% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $3.93 | +154.45% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $17.00 | +252.94% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $1.55 | +287.10% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $4.25 | +135.29% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $1.60 | +14,900.00% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $10.40 | +1,650.00% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $180 → $80 | $0.21 | +37,423.45% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $5.39 | +271.06% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.84 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.55 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.31 | +159.74% | 1 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $6.01 | +249.71% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $7.20 | +145,733.33% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $2.22 | +1,566.67% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $60.55 | +395.46% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $600.00 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $86.85 | +2.48% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $137.03 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Speculative Buy | $15,000 | $3.89 | +385,504.11% | 1 | Jun 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $2.43 | +13,727.16% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.86 | +270.37% | 1 | Mar 19, 2020 |
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $5.26
Upside: +109.13%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $17.40
Upside: +78.16%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $0.95
Upside: +1,889.74%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $7.19
Upside: +192.07%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $3.70
Upside: +35.14%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $1.91
Upside: +737.70%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $120
Current: $1.60
Upside: +7,400.00%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $7.36
Upside: +239.67%
Spruce Biosciences
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $8.82
Upside: -
Biodexa Pharmaceuticals
Feb 8, 2024
Initiates: Buy
Price Target: $2,000
Current: $6.85
Upside: +29,097.08%
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.44
Upside: +386.11%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $3.93
Upside: +154.45%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $17.00
Upside: +252.94%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $1.55
Upside: +287.10%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $4.25
Upside: +135.29%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $1.60
Upside: +14,900.00%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $10.40
Upside: +1,650.00%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $180 → $80
Current: $0.21
Upside: +37,423.45%
Mar 7, 2023
Initiates: Buy
Price Target: $20
Current: $5.39
Upside: +271.06%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.84
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.55
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $2.31
Upside: +159.74%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $6.01
Upside: +249.71%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $7.20
Upside: +145,733.33%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $2.22
Upside: +1,566.67%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $60.55
Upside: +395.46%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $600.00
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $86.85
Upside: +2.48%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $137.03
Upside: -
Jun 16, 2020
Initiates: Speculative Buy
Price Target: $15,000
Current: $3.89
Upside: +385,504.11%
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $2.43
Upside: +13,727.16%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $4.86
Upside: +270.37%